Market Overview

AbbVie Receives An Upgrade From Vetr

With $36.7B In Cash, Bank of America Expects Gilead To Shop For Complements To Drug Pipeline
Benzinga's Weekly Bulls & Bears: AbbVie, Kinder Morgan, Paypal, Starbucks, Wynn And More
Multiple Double-Digit Payout Increases In The First 2 Weeks Of February (Seeking Alpha)

On Tuesday, the Vetr crowd upgraded their rating for AbbVie Inc (NYSE: ABBV), from 3 stars (Hold), issued four days ago, to 4.5 stars (Strong Buy). At the time of the upgrade, crowd sentiment for AbbVie was generally positive, with 63 percent of Vetr user ratings bullish.

Share price in the biopharma company has been trending up since mid-February, gaining over 8.5 percent. In that span, AbbVie released a solid Q4 earnings report, meeting an EPS estimates and just missing revenue estimates. The stock also picked up an upgrade from Goldman Sachs who put the stock at Buy.

By today's close, AbbVie was down slightly on the day at $65.67

Learn how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for AbbVie is up at $74.72, which is above the average analyst target price of $70.33. Less than 2 percent of Vetr users are holding ABBV in their watch lists

Latest Ratings for ABBV

Feb 2018ArgusMaintainsBuy
Jan 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Jan 2018BMO CapitalDowngradesMarket PerformUnderperform

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: VetrBiotech Upgrades Price Target Crowdsourcing Analyst Ratings


Related Articles (ABBV)

View Comments and Join the Discussion!